Insmed Incorporated (INSM)

Last Price$81.1(3.0%)

Market Cap$14.5B

LTM EBITDA

($848.9M)

YoY Growth

+30.4%

3Y CAGR

+31.4%

5Y CAGR

+31.5%

Stock quality & Intrinsic value

6/10

51.1% overvalued

INSM

is (51.1%) overvalued

learn more -->

50+

undervalued stocks

Start beating the S&P 500

Insmed Incorporated EBITDA

Annual

Quarterly

LTM

Crunching data... Almost there!

	Dec'04	Dec'05	Dec'06	Dec'07	Dec'08	Dec'09	Dec'10	Dec'11	Dec'12	Dec'13	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23
EBITDA	($27.2M)	($13.8M)	($49.1M)	($18.9M)	($13.4M)	$120.3M	($6,193.0K)	($59.3M)	($40.1M)	($54.2M)	($86.1M)	($115.3M)	($170.2M)	($184.1M)	($293.8M)	($215.7M)	($250.4M)	($375.1M)	($429.4M)	($660.2M)

INSM

Key metrics and insights to make informed decisions.

View full analysis

Overvalued or undervalued?

Check the intrinsic value for INSM and see if it's the right time to invest.

Dive in

Insmed Incorporated (INSM) EBITDA comparison analysis

Crunching data... Almost there!

INSM key stats

USD

Millions

Billions

Annual

Quarterly

Trailing

Key stats

Income statement

Balance sheet

Cash Flow Statement

Valuation

Ratios

Per share

Per employee

Dividends & Yields

Crunching data... Almost there!

Discover more Stock Ideas

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%

S&P Outperformance 19.1%

Next 3M Predicted Return 20.3%

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%

S&P Outperformance 22.3%

Next 3M Predicted Return 26.8%

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.

3M Return 28.4%

S&P Outperformance 15.4%

Next 3M Predicted Return 16.9%

More ideas -->

FAQ

1) What is Insmed Incorporated's EBITDA?

As of today, Insmed Incorporated's last 12-month EBITDA is ($848.9M), based on the financial report for Dec 31, 2024 (Q4 2024).

2) What is Insmed Incorporated's EBITDA growth rate?

Over the last year, Insmed Incorporated's EBITDA growth was 30.4%. The average annual EBITDA growth rates for Insmed Incorporated have been 38.2% over the past three years, 31.5% over the past five years.

3) Is Insmed Incorporated's EBITDA growth rate Good?

Over the last year, Insmed Incorporated's EBITDA growth was 30.4%, which is higher than industry growth of (0.1%). It indicates that Insmed Incorporated's EBITDA growth is Good.

4) How does Insmed Incorporated's EBITDA growth rate compare to its peers?

Over the last year, Insmed Incorporated's EBITDA growth was 30.4%, which is higher than peer median growth of (89.1%). The list of peers includes NVO, REGN, UTHR, VRTX, INCY, ARGX, SMMT, ALNY, BNTX, BGNE etc.